A share price of Sagimet Biosciences Inc [SGMT] is currently trading at $5.42, down -5.41%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SGMT shares have gain 16.56% over the last week, with a monthly amount drifted -15.18%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, March 2024, Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat. In a post published today on Yahoo Finance, Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the completion of a Phase 1 hepatic impairment study with denifanstat, a selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
From an analyst’s perspective:
Sagimet Biosciences Inc [NASDAQ: SGMT] stock has seen the most recent analyst activity on March 25, 2024, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $26. On August 08, 2023, Piper Sandler initiated with a Overweight rating and assigned a price target of $67 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $30 on August 08, 2023. Goldman initiated its recommendation with a Buy and recommended $33 as its price target on August 08, 2023.
Sagimet Biosciences Inc experienced fluctuations in its stock price throughout the past year between $2.13 and $20.71. Sagimet Biosciences Inc [NASDAQ: SGMT] shares were valued at $5.42 at the most recent close of the market.
Analyzing the SGMT fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -14.33%, Pretax Profit Margin comes in at -13.46%, and Net Profit Margin reading is -13.46%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is 0.22 and Total Capital is -0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.16 points at the first support level, and at 4.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.87, and for the 2nd resistance point, it is at 6.31.
Sagimet Biosciences Inc [SGMT] reported earnings per share of -$0.78 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.58/share, meaning a difference of -$0.2 and a surprise factor of -34.50%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.35 per share as compared to estimates of -$0.99 per share, a difference of $0.64 representing a surprise of 64.60%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Sagimet Biosciences Inc [NASDAQ:SGMT] is 17.04. In addition, the Quick Ratio stands at 17.04 and the Cash Ratio stands at 20.17. Considering the valuation of this stock, the price to sales ratio is 62.06, the price to book ratio is 1.36.
Transactions by insiders
Recent insider trading involved Happel David, President & CEO, that happened on Mar 26 ’24 when 12100.0 shares were purchased. President & CEO, Happel David completed a deal on Dec 07 ’23 to buy 1600.0 shares. Meanwhile, President & CEO Happel David bought 590.0 shares on Nov 16 ’23.
